H
Hans-Rudolf Raab
Researcher at University of Oldenburg
Publications - 35
Citations - 5090
Hans-Rudolf Raab is an academic researcher from University of Oldenburg. The author has contributed to research in topics: Chemoradiotherapy & Colorectal cancer. The author has an hindex of 13, co-authored 35 publications receiving 4368 citations.
Papers
More filters
Journal ArticleDOI
Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years
Rolf Sauer,Torsten Liersch,Susanne Merkel,Rainer Fietkau,Werner Hohenberger,Clemens F. Hess,Heinz Becker,Hans-Rudolf Raab,Marie-Therese Villanueva,Helmut Witzigmann,Christian Wittekind,Tim Beissbarth,Claus Rödel +12 more
TL;DR: In this paper, the authors reported long-term results with a median follow-up of 134 months, where they found a difference of 10% in 5-year overall survival as the primary end point.
Journal ArticleDOI
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Gunnar Folprecht,Thomas Gruenberger,Wolf O. Bechstein,Hans-Rudolf Raab,Florian Lordick,Jörg T. Hartmann,Hauke Lang,Andrea Frilling,Jan Stoehlmacher,Jürgen Weitz,Ralf Konopke,Christian Stroszczynski,Torsten Liersch,Detlev Ockert,Thomas Herrmann,Eray Goekkurt,Fabio Parisi,Claus-Henning Köhne +17 more
TL;DR: In this paper, the effectiveness of cetuximab combined with chemotherapy in this setting was assessed, and the primary endpoint was tumour response assessed by Response Evaluation Criteria In Solid Tumours (RECIST), analysed by modified intention to treat.
Journal ArticleDOI
Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates
TL;DR: Patient selection and efficacy of pre-operative chemotherapy are both strong predictors for resectability of liver metastases, and a strong correlation was found between response rates and the resection rate.
Journal ArticleDOI
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial
Claus Rödel,Torsten Liersch,Heinz Becker,Rainer Fietkau,Werner Hohenberger,Torsten Hothorn,Torsten Hothorn,Ullrich Graeven,Dirk Arnold,Marga Lang-Welzenbach,Hans-Rudolf Raab,Heiko Sülberg,Christian Wittekind,Sergej Potapov,Ludger Staib,Clemens F. Hess,Karin Weigang-Köhler,Gerhard G. Grabenbauer,Hans Hoffmanns,Fritz Lindemann,Anke Schlenska-Lange,Gunnar Folprecht,Rolf Sauer +22 more
TL;DR: This phase 3 study integrated oxaliplatin into standard treatment in patients with histologically proven carcinoma of the rectum with clinically staged T3-4 or any node-positive disease to improve disease-free survival (DFS).
Journal ArticleDOI
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
Claus Rödel,Claus Rödel,Ullrich Graeven,Rainer Fietkau,Werner Hohenberger,Torsten Hothorn,Torsten Hothorn,Dirk Arnold,Ralf-Dieter Hofheinz,Michael Ghadimi,Hendrik A. Wolff,Marga Lang-Welzenbach,Hans-Rudolf Raab,Christian Wittekind,Philipp Ströbel,Ludger Staib,Martin Wilhelm,Gerhard G. Grabenbauer,Hans Hoffmanns,Fritz Lindemann,Anke Schlenska-Lange,Gunnar Folprecht,Rolf Sauer,Torsten Liersch +23 more
TL;DR: In this paper, the authors compared the previously established regimen with an investigational regimen in which oxaliplatin was added to both preoperative chemoradiotherapy and postoperative chemotherapy.